USA flag logo/image

An Official Website of the United States Government

STTR Phase I: Novel Production Platform for Synthesis of Toxic Enzymes

Award Information

Agency:
National Science Foundation
Branch:
N/A
Award ID:
88487
Program Year/Program:
2008 / STTR
Agency Tracking Number:
0740643
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
APC BIOTECHNOLOGY SERVICES, INC.
APC BIOTECHNOLOGY SERVICES, INC. 9610 Medical Center Drive Rockville, MD 20850
View profile »
Woman-Owned: Yes
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2008
Title: STTR Phase I: Novel Production Platform for Synthesis of Toxic Enzymes
Agency: NSF
Contract: 0740643
Award Amount: $150,000.00
 

Abstract:

This Small Business Technology Transfer Phase I research develops a novel bioprocess platform for the synthesis of toxic enzymes as inactive pro-enzymes in bacteria that can subsequently be activated via simple pH and/or temperature shifts. Recombinant enzymes for industrial synthetic applications or pharmacologic replacement therapies can be very difficult and expensive to produce in large quantities in an active form because they are toxic to the host, self-inactivate, or both. Numerous proteases, digestive enzymes, and cross-linking enzymes that break down or build up macromolecular complexes with high commercial potential are all but impossible to isolate in active form. The company proposes to use the catalytic core of the human transglutaminase 1 enzyme (TG1) to prove the concept. This research could have a direct impact on patients suffering from a severe form of ?scaly skin? disease, known as lamellar icthyosis, who have a defect in their TG1 gene. The broader impacts of this research are development of novel biomaterials and/or processes for several industries, including biotechnology, food processing, cosmetics and skin care (non-pharmacologic), detergents, and possibly waste remediation. Recombinant transglutaminases will specifically enable the development of novel types of biopolymers and materials. The research with TG1 could have a broader impact in the biomedical industry because it may lead to the development of a TG1-based ?liquid bandage? product for use in treatment of wounds, burns and cosmetic/reconstructive surgeries.

Principal Investigator:

Aprile L. Pilon
DPhil
3014522899
apilon@apcbio.com

Business Contact:

Aprile L. Pilon
DPhil
3014522899
apilon@apcbio.com
Small Business Information at Submission:

APC Biotechnology Services, Inc.
13328 Manor Stone Drive Germantown, MD 20874

EIN/Tax ID: 342052911
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
Princeton University
E-Quad
Princeton, NJ 8544
Contact: David Wood
Contact Phone: (301) 452-2899
RI Type: Nonprofit college or university